Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases

Respiration

Volumn 91, Issue 4, 2016, Pages 296-301

  Schupp, Jonas Christian ^a   Köhler, Thomas ^a   Müller Quernheim, Joachim ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cyclophosphamide; Idiopathic pulmonary fibrosis; Interstitial lung disease; Lymphocytic interstitial pneumonia

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG PULSE THERAPY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG FUNCTION; LUNG LAVAGE; LYMPHOCYTIC INTERSTITIAL PNEUMONIA; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASE; TOTAL LUNG CAPACITY; AGED; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOTAL LUNG CAPACITY;

EID: 84973468899     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000445031     Document Type: Article

References (30)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2011 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Fischer A, Lee JS, Cottin V: Interstitial lung disease evaluation: detecting connective tissue disease. Respiration 2015; 90: 177-184.
3. Paschalaki KE, Jacob J, Wells AU: Monitoring of lung involvement in rheumatologic disease. Respiration 2016; 91: 89-98.
4. Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Maniati M, Borie R, et al: Investigation of lung involvement in connective tissue disorders. Respiration 2015; 90: 2-24.
5. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
6. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, et al: Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125: 2169-2174.
7. Baughman RP, Lower EE: Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102: 1090-1094.
8. Roig V, Herrero A, Arroyo-Cózar M, Vielba D, Juarros S, Macías E: Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis (in Spanish). Arch Bronconeumol 2010; 46: 15-19.
9. Pereira CAC, Malheiros T, Coletta EM, Ferreira RG, Rubin AS, Otta JS, et al: Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids. Respir Med 2006; 100: 340-347.
10. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
11. Oltmanns U, Kahn N, Palmowski K, Träger A, Wenz H, Heussel CP, et al: Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199-207.
12. Jones MG, Fletcher S, Richeldi L: Idiopathic pulmonary fibrosis: recent trials and current drug therapy. Respiration 2013; 86: 353-363.
13. Antoniou KM, Symvoulakis EK, Anyfantakis D, Wells AU: New treatments for idiopathic pulmonary fibrosis: 'die another day' if diagnosed early? Respiration 2015; 90: 352.
14. Robles-Perez A, Molina-Molina M: Treatment considerations of lung involvement in rheumatologic disease. Respiration 2015; 90: 265-274.
15. Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A: Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 2013; 12: 1076-1084.
16. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al: Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63(suppl 5):v1-v58.
17. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
18. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al: Rituximab versus azathioprine for maintenance in ANCAassociated vasculitis. N Engl J Med 2014; 371: 1771-1780.
19. Cha S-I, Fessler MB, Cool CD, Schwarz MI, Brown KK: Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006; 28: 364-369.
20. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
21. Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al: Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
23. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al: Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-522.
24. Prasse A, Georges CG, Biller H, Hamm H, Matthys H, Luttmann W, et al: Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol 2000; 122: 241-248.
25. Antoniou KM, Wells AU: Acute exacerbations of idiopathic pulmonary fibrosis. Respiration 2013; 86: 265-274.
26. Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S: Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study. Respiration 2015; 89: 201-207.
27. Leuchte HH, Mernitz P, Baezner C, Baumgartner RA, von Wulffen W, Neurohr C, et al: Self-report daily life activity as a prognostic marker of idiopathic pulmonary fibrosis. Respiration 2015; 90: 460-467.
28. Martin F, Lauwerys B, Lefèbvre C, Devogelaer JP, Houssiau FA: Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254-257.
29. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al: The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
30. Joo HP, Dong SK, Park IN, Se JJ, Kitaichi M, Nicholson AG, et al: Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.